Healthcare / BiotechnologyKOSDAQ
$3430.00
-100.00 (-2.83%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-16.9B · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$117.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-27.9%
↓Gross Margin
9.9%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-349.7%
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.90B · net income $-12.81B · FCF $-13.63B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.90B | $3.90B | — | — | — |
| Net Income | $-12.81B | $-12.81B | $-20.14B | $-35.32B | $-35.75B |
| EBITDA | $-11.54B | $-11.54B | $-18.51B | $-33.00B | $-24.27B |
| EPS | -374.00 | -374.00 | -598.00 | -1665.00 | -917.86 |
| Gross Margin | 9.9% | 9.9% | — | — | — |
| Operating Margin | -359.6% | -359.6% | — | — | — |
| Net Margin | -328.6% | -328.6% | — | — | — |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.03 | 0.03 | 1.96 |
| Current Ratio | 26.54 | 26.54 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-13.63B | $-13.63B | $-16.88B | $-26.47B | $-30.54B |
| Returns | |||||
| ROE | -27.9% | -27.9% | -34.9% | -49.8% | -110.6% |
| Valuation | |||||
| P/B | 2.56 | 2.56 | 2.70 | 1.95 | 14.43 |
| Growth & Yield | |||||
| EPS Growth | 37.5% | 37.5% | 64.1% | -81.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-598.00 → -374.00
Residual
+0.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.